Toxins

biotechnology advances

[1] Consolidated bio-saccharification: Leading lignocellulose bioconversion into the real world.

[2] recent developments of the synthetic biology toolkit for clostridium

[3] a combination of extreme environmental conditions favor the prevalence of endospore-forming firmicutes

[4] treating clostridium difficile infections: should fecal microbiota transplantation be reclassified from investigational drug to human tissue?

[5] presence of toxic microbial metabolites in table olives

[6] Vaccine Production to Protect Animals Against Pathogenic Clostridia.

[7] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

[8] Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

[9] Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

[10] Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

[11] Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

[12] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

[13] National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

[14] An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

[15] Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

[16] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

[17] Community-acquired Clostridium difficile infection: an increasing public health threat

[18] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

[19] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

[20] Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

[21] Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

[22] Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

[23] Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

[24] Endogenous Clostridium perfringens Panophthalmitis with Potential Entry Port from Diverticulitis Exacerbated by Proliferative Diabetic Retinopathy

[25] Decreased Clostridium Abundance after Electroconvulsive Therapy in the Gut Microbiota of a Patient with Schizophrenia

[26] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

[27] National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

[28] An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

[29] Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

[30] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

[31] Community-acquired Clostridium difficile infection: an increasing public health threat

[32] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

[33] A Novel Quantitative Sampling Technique for Detection and Monitoring of Clostridium difficile Contamination in the Clinical Environment.

[34] Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia

[35] σ ⁵⁴ (σ ^L ) plays a central role in carbon metabolism in the industrially relevant Clostridium beijerinckii

[36] Correction to: Fed-batch acetone-butanol-ethanol fermentation using immobilized Clostridium acetobutylicum in calcium alginate beads (Korean Journal of Chemical Engineering, (2019), 36, 6, (909-913), 10.1007/s11814-018-0232-z)

[37] Analyses of miRNA in the ileum of diarrheic piglets caused by Clostridium perfringens type C.

[38] Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system

[39] Growth of Clostridium perfringens in cooked chicken during cooling: One-step dynamic inverse analysis, sensitivity analysis, and Markov Chain Monte Carlo simulation

[40] Clostridium botulinum Spores Found in Honey from Small Apiaries in Poland

[41] Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection.

[42] Erratum: Correction for Kraft et al., "A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults" (Clinical microbiology reviews (2019) 32 3 PII: e00128-19)

[43] Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.

[44] Clostridium difficile: Is it a new food-borne pathogen?

[45] Use of fluorescent CTP1L endolysin cell wall-binding domain to study the evolution of Clostridium tyrobutyricum during cheese ripening.

[46] Effect of detoxification methods on ABE production from corn stover hydrolysate by Clostridium acetobutylicum CICC 8016.

[47] Flooding-Associated Soft Rot of Sweetpotato Storage Roots Caused by Distinct Clostridium Isolates

[48] Detection of Clostridium perfringens toxinotypes, enteropathogenic e. coli, rota and corona viruses in the intestine of neonatal goat kids by molecular techniques

[49] Clostridium cellulovorans metabolism of cellulose as studied by comparative proteomic approach.

[50] Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance

[51] Butanol production from cellulosic material by anaerobic co-culture of white-rot fungus Phlebia and bacterium Clostridium in consolidated bioprocessing.

[52] Thermodynamic Analysis of Glycolysis in Clostridium thermocellum and Thermoanaerobacterium saccharolyticum Using C and H Tracers.

[53] The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.

[54] Evaluation of factors influencing the growth of non-toxigenic Clostridium botulinum type E and Clostridium sp. in high-pressure processed and conditioned tender coconut water from Thailand

[55] Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

[56] Bacterial Diarrhea in HIV-Infected Patients: Why Clostridium difficile, and Why Now?

[57] Clostridium difficile infection in fever patients with gynecological malignancies

[58] Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection

[59] Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

[60] Differences of the Fecal Microflora With Clostridium difficile Therapies

[61] Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship

[62] Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients

[63] Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

[64] Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients

[65] Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens.

[66] Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

[67] Epidemiology of community-acquired Clostridium difficile-associated diarrhea

[68] A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)

[69] Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study

[70] Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections

[71] Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study

[72] Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals

[73] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

[74] Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

[75] A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

[76] Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens

[77] Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

[78] Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens

[79] Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection

[80] Prevalence and Pathogenicity of Clostridium difficile in Hospitalized Patients: A French Multicenter Study

[81] Factors affecting initiation of growth of Clostridium botulinum

[82] Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis

[83] Pathway to Prevention of Nosocomial Clostridium difficile Infection

[84] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

[85] Duodenal infusion of donor feces for recurrent Clostridium difficile

[86] Risk factors for Clostridium difficile toxin-associated diarrhea

[87] John G. Bartlett: Contributions to the Discovery of Clostridium difficile Antibiotic-Associated Diarrhea

[88] Prevention of Clostridium difficile Infection With Probiotics

[89] Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection

[90] Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

[91] Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients

[92] Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS

[93] Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

[94] Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

[95] Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors

[96] Epidemiology of Community-Acquired Clostridium difficile-Associated Diarrhea

[97] Comparison of Clindamycin, Rifampin, Tetracycline, Metronidazole, and Penicillin for Efficacy in Prevention of Experimental Gas Gangrene Due to Clostridium perfringens

[98] The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

[99] Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015

[100] clostridium perfringens e a enterite necrótica em frangos: principais fatores de virulência, genéticos e moleculares

[101] pseudomembranous colitis: not always caused by clostridium difficile